The estimated Net Worth of Nailesh Bhatt is at least 25.1 千$ dollars as of 17 May 2023. Nailesh Bhatt owns over 25,000 units of Sonnet BioTherapeutics Inc stock worth over 25,057$ and over the last 5 years Nailesh sold SONN stock worth over 0$.
Nailesh has made over 1 trades of the Sonnet BioTherapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Nailesh bought 25,000 units of SONN stock worth 5,750$ on 17 May 2023.
The largest trade Nailesh's ever made was buying 25,000 units of Sonnet BioTherapeutics Inc stock on 17 May 2023 worth over 5,750$. On average, Nailesh trades about 5,000 units every 0 days since 2020. As of 17 May 2023 Nailesh still owns at least 30,733 units of Sonnet BioTherapeutics Inc stock.
You can see the complete history of Nailesh Bhatt stock trades at the bottom of the page.
Nailesh's mailing address filed with the SEC is 100 OVERLOOK CENTER, SUITE 102, , PRINCETON,, NJ, 08540.
Over the last 8 years, insiders at Sonnet BioTherapeutics Inc have traded over 53,380$ worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth 290,512$ . The most active insiders traders include Pankaj Mohan、Donald J. Griffith、Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of 21,474$. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth 12,739$.
sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies
Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include: